Navigation Links
Gleevec Prevents Return of Intestinal Cancer, Study Confirms
Date:3/19/2009

Drug is shown to be most effective on larger tumors

THURSDAY, March 19 (HealthDay News) -- Taking Gleevec after surgery to remove a gastrointestinal stromal tumor improves tumor-free survival, a U.S. study has confirmed.

Gastrointestinal stromal tumors (GIST), the most common soft-tissue cancer of the intestinal tract, typically occur in the stomach or small intestine. About 3,000 to 4,000 cases are diagnosed in the United States each year. According to background information in the study, about 85 percent of these tumors have a protein that allows them to be inhibited by Gleevec, known as imatinib.

The finding stems from a phase 3 trial for the drug, which was approved last year by the U.S. Food and Drug Administration to treat people who've had surgery to remove a GIST. The drug already was approved for treating certain types of adult leukemia.

The trial included more than 700 people with a GIST at least 3 centimeters in size that tested positive for the protein. The participants were randomly selected to take either 400 milligrams of Gleevec or a placebo once a day for a year after surgery to remove their tumor.

After a median follow-up of almost 20 months, 8 percent of people in the Gleevec group and 20 percent of those in the placebo group had experienced tumor recurrence or had died. After a year, recurrence-free survival was 98 percent for those taking the drug and 83 percent for people taking the placebo.

Tumor size affected treatment success, the study found. Gleevec had the most effect on tumors that were 10 cm or larger, less effect on tumors between 6 and 10 cm, and the least effect on tumors between 3 and 6 cm, the study reported.

The most common serious side effects experienced by people taking the drug were dermatitis, abdominal pain and diarrhea.

Dr. Ronald DeMatteo, of Memorial Sloan-Kettering Cancer Center, and his fellow researchers said that their "findings will affect the management of patients with primary gastrointestinal stromal tumor and could have relevance to the adjuvant use of other molecular agents for cancer."

The study appears online and in an upcoming print issue of The Lancet.

Dr. Peter Hohenberger, of the University of Heidelberg, in Mannheim, Germany, said in an accompanying comment that more research is needed.

"There are so many unknowns that this trial might not be able to provide a definitive treatment decision," he wrote. "To refine the indication for adjuvant treatment remains the big task for future studies."

More information

The American Cancer Society has more about GIST.



-- Robert Preidt



SOURCE: The Lancet, news release, March 18, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports
2. Prescription Copay Assistance for Patients taking Gleevec or Tasigna for Philadelphia chromosome-positive Chronic Myelogenous Leukemia (Ph+ CML)
3. Cancer Drug Gleevec Could Fight Stroke
4. Cancer Drug Gleevec Linked to Muscle Damage
5. Protein predicts Gleevec resistance in gastrointestinal tumors
6. Gleevec Pushes Advanced Melanoma Into Remission
7. Gleevec May Disrupt Ovarian Function
8. Photo: New Data Show Gleevec(R) Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment
9. Gleevec, the targeted cancer pill, delivers more good news to patients
10. Cell pathway on overdrive prevents cancer response to dietary restriction
11. New surgical implant tested at U-Iowa prevents total blindness
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gleevec Prevents Return of Intestinal Cancer, Study Confirms
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth published data from ... type 2 diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels ... in public health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and ...
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi ... and 11th, 2016 in honor of his birthday on February 10th. During this ... Mahendra Trivedi is known by over 250,000 people from over 40 different countries as ...
(Date:2/7/2016)... ... February 07, 2016 , ... Women's Excellence staff, in all ... Day. National Wear Red Day is the first Friday each February and a ... stroke cause 1 in 3 deaths among women each year – more than all ...
(Date:2/6/2016)... ... , ... US Sports Camps is proud to sponsor the Bay Area Disc ... non-profit leaders, ultimate organizations, and coaches from around the US. The theme for this ... Director of Youth and Education, describes this year YUCC as “an important conversation we ...
(Date:2/5/2016)... ... February 05, 2016 , ... Steven Tonkinson, 36, of ... completed every year since it started in 2003. This year, he ran all 26.2 ... fellow runners and NBA team the Miami Heat. , This Sunday, while many are ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... 2016   Intarcia Therapeutics, Inc. today announced ... into the newly created role of Vice President, Head ... has two decades of leadership experience at leading pharmaceutical, ... academic medical center. Most recently Dr. Yee served as ... US Head Medical Officer at AstraZeneca, where he led ...
(Date:2/8/2016)... PAOLI, Pa. , Feb. 8, 2016  As part ... Ltd has announced today the appointment of Lori Chmura ... more than 20 years in the industry, Chmura,s extensive experience ... in the advancement of Dune Medical Devices. ... Lori will be responsible for leading all sales, marketing and ...
(Date:2/8/2016)... 2016  Avista Pharma Solutions ("Avista Pharma") announced today ... Financial Officer (CFO). Mr. Setzer is a finance and ... various roles within growing technology and life science companies. ... Executive Director of Finance at INC Research, a publicly ... . Previously, Mr. Setzer served as CFO of ...
Breaking Medicine Technology: